Pharma Focus Europe

SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)

Wednesday, July 27, 2022

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, has announced that it has exercised its first exclusive option with LegoChem Biosciences for the antibody-drug conjugate (ADC) SOT106. The ADC is currently undergoing preclinical studies for various solid tumor indications.

In November 2021, SOTIO and LegoChem Biosciences entered into a multi-target exclusive collaboration and license agreement, granting SOTIO the rights to utilize LegoChem's ADC technology for up to five ADC programs. SOTIO is responsible for the research, development, manufacturing, and global commercialization of the ADC products.

Dr. Radek Spisek, CEO of SOTIO, expressed satisfaction with the progress made on their innovative ADC pipeline, highlighting the advancement of their lead program, SOT102, targeting CLDN18.2, into the Phase 1 portion of the CLAUDIO-01 trial. He also emphasized the promising potential of SOT106, an ADC designed to address challenging solid tumor indications, based on preclinical studies. Dr. Spisek reaffirmed SOTIO's commitment to providing effective and safe therapeutic options for cancer patients.

Dr. Yong-Zu Kim, CEO and President of LegoChem Biosciences, expressed excitement about the successful outcome achieved in a relatively short period since the partnership began. He attributed the achievement to the combination of SOTIO's expertise in antibody discovery and LegoChem's industry-leading ADC platform technology. Dr. Kim looks forward to further progress in their partnership, generating new drug candidates through an efficient and close collaboration.

The exercise of the first option will result in an undisclosed milestone payment from SOTIO to LegoChem Biosciences.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva